Don Black, Head of R&D, Medical Diagnostics at GE Healthcare said: "We were excited to see the results from this Phase I study with GE-067 and as a result have initiated a larger study with manufacturing and scanning centres across Europe. We also plan to extend our studies to the United States of America."
Commenting on the results, Rik Vandenberghe, Principal Investigator of the trial and Professor of Neurology at the University of Leuven, Belgium said "The results of this Phase I trial are a very encouraging step forward in our quest to develop a clinically useful diagnostic imaging agent to assist in the early diagnosis of Alzheimer's Disease and directly demonstrate in vivo the presence of abnormal quantities of beta amyloid in an individual's brain. With latest estimates of the incidence of Alzheimer's Disease predicted to quadruple to 106 million by 20503 and with the potential development of amyloid -lowering therapies, there is a critical need for an effective diagnostic product to directly and reliably demonstrate the presence of amyloid deposits as early as possible during the course of the disease and ultimately improve the lives of patients and caregivers."
Ad Statistics
Times Displayed: 19090
Times Visited: 362 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
The PIB series of compounds are licensed by GE Healthcare from The University of Pittsburgh. In 2008, the inventors of PIB, William E. Klunk, MD, PhD, and Chester A. Mathis, PhD, from the University of Pittsburgh, were awarded the prestigious American Academy of Neurology Potamkin Prize for their significant contribution to the imaging of amyloid.
About Alzheimer Disease
Alzheimer's disease is the most common cause of dementia and a leading cause of death worldwide.
Latest estimates put the global prevalence at 26.6 million and forecast that by 2050 the prevalence will quadruple, to leave 1 in 85 people worldwide living with the disease3.
References:
1. Phase I study of the 18F-labelled benzothiazole derivative [18F]AH110690 as a biomarker of AD-related brain amyloidosis Rik Vandenberghe1 et al,. Poster Presentation, International Conference on Alzheimer's Disease 2008.
2. Post-mortem correlates of in vivo PIB-PET amyloid imaging in a typical case of Alzheimer's disease Ikonomovic, M.D. et al. Brain 2008 Jun; 131(Pt 6):1630-45.
3. Forecasting the global burden of Alzheimer's disease. R. Brookmeyer, et al. Alzheimer's and Dementia 2007, Volume 3, Issue 3, Pages 186 - 191.
Back to HCB News
